Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
+$0.14 today
- Market cap
- $50.18M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
Volume 0.66M
Average 0.42M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
Intrinsic Alpha fair value
Locked
Current Price
$2.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Forte Biosciences, Inc. NASDAQ:FBRX | $1.63B | $76.99 | Not rated | -42.1 | +311.49% |
Alector, Inc. NASDAQ:ALEC | $378.15M | $2.54 | Not rated | -1.4 | +88.52% |
PepGen Inc. NASDAQ:PEPG | $301.98M | $4.36 | Not rated | -1.6 | -28.93% |
Innate Pharma S.A. NASDAQ:IPHA | $154.15M | $1.38 | Not rated | -3.0 | -47.49% |
Molecular Partners AG NASDAQ:MOLN | $112.71M | $2.94 | Not rated | -2.0 | -38.90% |
Milestone Pharmaceuticals Inc. NASDAQ:MIST | $64.74M | $0.52 | Not rated | -2.5 | -80.24% |
Cardiff Oncology, Inc. NASDAQ:CRDF | $56.49M | $0.73 | Not rated | -1.8 | -55.37% |
Rani Therapeutics Holdings, Inc. NASDAQ:RANI | $34.38M | $0.53 | Not rated | -4.6 | -54.34% |
Elicio Therapeutics, Inc. NASDAQ:ELTX | $28.60M | $1.50 | Not rated | -1.7 | -66.67% |
Continue the stock analysis
Jump to another research area for this company.